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E-mail: philippe.colson@ap-hm.frWe read with interest the recent article by Ippolito et al. [1] on
the need for a close virological monitoring of hepatitis C therapy
with new directly acting agents (DAAs). Sofosbuvir, the ﬁrst
commercially available hepatitis C virus (HCV) RNA polymerase
inhibitor, expands the therapeutic revolution initiated in 2011
with ﬁrst-generation HCV protease inhibitors [2]. This drug still
increases the rate of sustained virological response, regardless of
the viral genotype, and with a reduced duration of therapy (3–6
months). In addition, it can be associated with other DAAs
including daclatasvir and simeprevir, which avoids using the
poorly tolerated pegylated interferon and ribavirin in some
treatment combinations. Notwithstanding, sofosbuvir use has
raised some non-medical concern due to its very high cost,
which is ~66,000 Euros or 84,000 USD for a 12-week course of
therapy [3]. In addition, in several indications based on currentMicrobiol Infect 2015; 21: e32
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.10.021guidelines, the duration of sofosbuvir-based therapies is 24
weeks and not 12 weeks [4].We do agree with Ippolito et al. that
tight virological monitoring of these highly efﬁcient but expen-
sive HCV therapies is needed [1]. Nonetheless, there are other
issues that deserve to be addressed, which are DAA compliance
and exposure. Both can be assessed by therapeutic drug moni-
toring (TDM), which is currently not recommended [4].
Our attention was recently attracted by nonresponse to an
8-week course of therapy with sofosbuvir and ribavirin in a 73-
year-old HIV-negative woman with HCV genotype 1b infection.
Indeed, HCV RNA level was 5.6 log10 IU/mL at baseline, and 5.4
and 5.6 log10 IU/mL after 4 and 8 weeks of therapy, respec-
tively. In this case, sofosbuvir TDM was not available in our
institution, but ribavirin concentration trough was undetectable
at week 8 of therapy, suggesting possible concurrent
noncompliance to sofosbuvir, although sofosbuvir-plus-rivabirin
therapy does not have 100% success.
TDM can allow detecting suboptimal drug exposure related
to noncompliance, and its cost is negligible compared to the
great expense of a full course of therapy with sofosbuvir [3].
HCV cure is now an achievable goal for a large majority of
patients, but at a high ﬁnancial cost, and this considerable
therapeutic advance could be locked by cheap laboratory
testing, at least in the case of non-response. TDM should also
apply to other newly available DAAs whose price is in the same
order of magnitude as that of sofosbuvir [3].Transparency declarationAll authors declare no conﬂicts of interest.References[1] Ippolito G, Antonelli G, Capobianchi MR, Lanini S. HCV treatment
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